Cell Analysis Global Market is estimated to be worth $38.0 billion by 2029

IQ4I Research & Consultancy published a new report on “Cell Analysis Global Market – Forecast To 2029” This report analyzes and studies the overall market, major Drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and Rest of the World.

IQ4I’s Report Contains 144 market data tables and 106 figures spread through 709 pages and an exhaustive TOC on “Cell Analysis Global Market”, [TECHNIQUES (PCR, Sequencing, Microfluidics & Microarrays, Microscopy, Cytometry, High Content Screening & Spectrometry, Electrophoresis and Others)); PRODUCTS (Consumables (Assay Kits, Reagents, Microplates, Others), Instruments (Cell Counters, Cell Microarray and Microfluidics, Liquid Handling Systems, Cytometers, High Content Screening, Microplate Readers, PCR Instruments, Sequencing Instruments, Spectrometers, Microscopes & Other instruments) Software and Services); APPLICATIONS (Based on Process, Based on-Field & Based on-Therapeutic areas); END-USERS (Hospitals & Diagnostic Labs, Academic & Research Institutes, Diagnostic Labs CROs, Pharma & Biotech Companies, Cell Banks, & Others); REGIONAL (North America, Europe, Asia Pacific and Rest of the World)]

Cell analysis encompasses a wide range of activities that help in understanding and predicting the dynamics that influence cell function, proliferation, growth and death. This is enabled through analysis of cell signaling mechanisms, elucidation of molecular function, study of cell behavior, and correlating to multiple events with cell morphology, changes in biochemical constituents and cell health. Cell analysis is gaining importance in various fields of applications such as drug discovery, diagnosis of infectious disease, cancer, genetic, neural, cardiac and others. Live-cell imaging, single-cell analysis, single cell spatial analysis, mass cytometry and high content screening (HCS) are some of the technological processes gaining more focus in recent times. Single-cell analysis and single cell spatial analysis is a rapidly evolving field where individual cells are analyzed for the assessment of changing cell behavior and function over time during its natural states or when perturbed by external factors, it is gaining prominence in the overall cell analysis market because of its extensive application in different research areas.

According to IQ4I analysis, the cell analysis global market is expected to grow at a low single digit CAGR from 2022 to 2029 to reach $38,020.6 million by 2029. The rising incidence of infectious and non-infectious diseases and demand for early detection, diagnosis & treatment, increasing government and private funding towards cell based research, increasing advancements in cell imaging technologies to reduce the cost & time during the drug discovery processes are driving the cell analysis market. Growing focus on personalized medicine and the introduction of advanced technologies in the cellular analysis process provides immense opportunities to the cell analysis market. However, stringent government regulations, availability of alternative technologies, lack of skilled personnel to use advanced cell analysis Instruments, and the high cost of some of the instruments are expected to hamper the market growth.

The cell analysis market is mainly segmented based on techniques, products, applications, end-users and geography. Based on the techniques, the cell analysis market is segmented into PCR, sequencing, microfluidics and microarrays, spectrometry, microscopy, cytometry, HCS (High content screening), electrophoresis and others. Among these techniques, PCR accounted for the largest revenue in 2022. Sequencing is expected to grow at a double digit CAGR from 2022 to 2029.

The cell analysis product market is segmented into consumables, instruments and software & services. Among these products, the Consumables segment is holding the largest share in 2022 and is expected to grow at a low single digit CAGR from 2022 to 2029 due to use of reagents, assay kits in diagnosis and research. Software and Services is expected to grow at mid single digit CAGR from 2022 to 2029.The consumables market is further sub-segmented into reagents, assay kits, microplates and others. Among the consumables sub-segments, the assay kits held the largest revenue in 2022. Reagents sub-segment is the fastest growing segment with a mid single digit CAGR from 2022 to 2029.

The instrument segment is further classified into cell counters, cell microarray and microfluidics, liquid handling systems, cytometers, high content screening (HCS) systems, microplate readers, PCR devices, sequencing instruments, spectrometer, microscopes and others. Among the instruments, the PCR instruments segment commanded the largest revenue in 2022 and is expected to grow at a CAGR of xx% from 2022 to 2029. Cell Microarrays and Microfluidics are expected to grow at a CAGR of low single digit CAGR from 2022 to 2029.

The cell analysis global market based on application is categorized into processes, technical field, disease, or therapeutic area. In the process of application, the market is segmented into cellular processes, signal transduction pathways, circulating tumor cells, single-cell analysis, epigenetic target analysis, subpopulation characterization, and drug and candidate screening. Cellular process application accounted for the largest revenue in 2022 and is expected to grow at a CAGR of xx% from 2022 to 2029 to reach $xx million by 2029. The single-cell analysis market is expected to boom at a high single digit CAGR from 2022 to 2029. Based on field of application, the market is further segmented into forensic, therapeutics, cell imaging, biomarker research, genomic analysis, stem cell analysis, and diagnostics. Diagnostics held the largest revenue in 2022. Stem cell analysis is the fastest-growing segment at a mid single digit CAGR from 2022 to 2029. Based on therapeutic area, the market is further segmented into cancer, infectious disease, genetic testing, immunology, and others. The Infectious diseases accounted for the largest revenue in 2022. Cancer is the fastest-growing segment with a mid single digit CAGR from 2022 to 2029.

The end-users market is segmented into hospitals & diagnostic laboratories, academic and research institutes, contract research organizations (CROs), pharmaceuticals and biotechnology companies, cell banks, and others. Hospitals & Diagnostic laboratories generated the largest revenue in 2022. Academic and research laboratories are expected to grow at a mid single digit CAGR from 2022 to 2029.

The cell analysis global market based on geography is segmented into North America, Europe, Asia-Pacific and the Rest of the world (RoW). North America accounted for the largest revenue in 2022 and is expected to reach $xx million by 2029 growing at a low single digit CAGR of from 2022 to 2029. The Asia-Pacific is the fastest-growing region in the cell analysis global market with a revenue of $xx million in 2022 and is expected to reach $xx million by 2029 growing at a low single digit CAGR from 2022 to 2029

Technological advancements are expanding the cell analysis market, particularly in single-cell analysis to enhance their application. Some of the major advancements in this field include CRISPER Live Cell Imaging, Raman Live Cell Imaging, Deep Learning and AI in Microscopy and development of Multi-Omics technologies, Droplet-Based Microfluidics, Inductively coupled plasma mass spectrometry (ICP-MS), Intelligent image-activated cell sorting or AI-driven cell isolation technology, Advanced spatial technologies, Digital Microfluidic Isolation of Single-cells for -Omics (DISCO) technologies in single-cell analysis. Recent advancements in microfluidic technologies have opened new avenues for single-cell genomics, transcriptomics, and proteomics, with a particular emphasis on quantification and multiplicity that can perform measurements on many single-cells. Various single-cell genomics, transcriptomics and proteomics solutions developed separately in recent decades, now the focus has been shifted towards the development of multi-omics methods. Along with these advancements in cell analysis, the trend is moving towards the merging of or combing various cell analysis technologies or integration of various technologies such as AI, which will have greater efficiency than the original and fills the gap between the technologies. Despite rapid advancements in single-cell isolation and analysis technologies, there is a gap between in single-cell omics analysis and in-situ analysis because current cell analysis technologies are unable to correlate the single-cell genomes, transcriptomes, or proteomes with the phenotypes of adherent cells in situ. Companies have realized the demand for these types of technologies, resulting in the development of innovative platforms single cell spatial analysis platforms to address the unmet needs, which will drive the demand for this market in the future. Due to the extensive advantages of cell analysis technologies in therapeutic discovery and development, Pharma & biotech companies, academic and research institutions and CRO are collaborating to utilize these technologies.

The widespread application of cell analysis attracts the government or private ventures to invest huge sums in this area to modernize the research and development. According to IQ4I research, during the period 2020-22*, approximately $xx million was invested by various venture capital and government agencies in cell analysis. In that, around $xx million funding is mainly focused on single-cell analysis.

The Cell analysis market is fragmented with the 6 top players occupying xx% of the market share and the remaining xx% of the market is occupied by other players. Companies are adopting various organic and inorganic strategies for market expansion.

Major players in the cell analysis market include Agilent Technologies, Inc. (U.S.), Becton Dickinson and Company (U.S.), Illumina Inc. (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands), Thermo Fisher Scientific, Inc. (U.S.), Roche Holdings, Inc. (Switzerland), Abbott Laboratories (U.S.) and 10X Genomics (U.S.)